For sodium tetrathiocarbonate and 8-hydroxyquinoline information has been presented and evaluated by the Commission together with Member States experts which has shown a need for further use of the substances concerned. It is therefore justified in the present circumstances to prescribe under strict conditions aimed at minimising risk a longer period for the withdrawal of existing authorisations for the limited uses considered as essential for which no efficient alternatives appear currently to be available.
Recital 4, Decision_act (EU) 2006/797
In forcesince 22 Nov 2006